Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Garnero

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Clinical Chemistry and Laboratory Medicine|November 22, 2024
Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone MetabolismGiovanni Lombardi, Niklas Rye Jørgensen, Nicholas C Harvey, et al.
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|March 9, 2007
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive proteinStephanie O Keeling, Robert Landewe, Desiree van der Heijde, et al.
Annals of the Rheumatic Diseases|May 10, 2011
ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitorsSusanne Juhl Pedersen, Inge Juul Sørensen, Patrick Garnero, et al.
Arthritis and Rheumatism|December 1, 2011
Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnoverSusanne Juhl Pedersen, Inge Juul Sørensen, Robert G W Lambert, et al.
The Journal of Rheumatology|August 13, 2009
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkersSilje W Syversen, Robert Landewe, Désirée van der Heijde, et al.
Age and Ageing|September 12, 2018
Developing a toolkit for the assessment and monitoring of musculoskeletal ageingGraham J Kemp, Fraser Birrell, Peter D Clegg, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Clinical Chemistry and Laboratory Medicine|November 22, 2024
Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone MetabolismGiovanni Lombardi, Niklas Rye Jørgensen, Nicholas C Harvey, et al.
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|March 9, 2007
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive proteinStephanie O Keeling, Robert Landewe, Desiree van der Heijde, et al.
Annals of the Rheumatic Diseases|May 10, 2011
ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitorsSusanne Juhl Pedersen, Inge Juul Sørensen, Patrick Garnero, et al.
Arthritis and Rheumatism|December 1, 2011
Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnoverSusanne Juhl Pedersen, Inge Juul Sørensen, Robert G W Lambert, et al.
The Journal of Rheumatology|August 13, 2009
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkersSilje W Syversen, Robert Landewe, Désirée van der Heijde, et al.
Age and Ageing|September 12, 2018
Developing a toolkit for the assessment and monitoring of musculoskeletal ageingGraham J Kemp, Fraser Birrell, Peter D Clegg, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Pageof 12